-
Mashup Score: 1
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the value of using circulating tumor cells (CTCs) in the prognosis of patients with newly diagnosed multiple myeloma (NDMM), highlighting the benefits of this approach over standard bone marrow assessments. Dr Paiva further comments on the feasibility and high reproducibility of this approach. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3IMS 2023 | VJHemOnc - 1 year(s) ago
The 20th International Myeloma Society (IMS) Annual Meeting will be held in Athens, Greece, from 27-30 September, 2023. This meeting will focus on the latest basic, preclinical, and clinical advances in the field of multiple myeloma. The 20th International Myeloma Society (IMS) Annual Meeting will be held in Athens, Greece, from 27-30 September, 2023. This meeting will focus on the latest basic, preclinical, and clinical advances in the field of multiple
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#IMS23 | So many wonderful updates in #MMsm! We caught up with @BrunoPaiva_UNAV this morning on immune profiling and cellular therapies, the value of circulating tumor cells in myeloma & more. Check out some of our congress coverage below: 👉https://t.co/EzCE1yK9yc… https://t.co/9NSqhXmgMK https://t.co/nG2LVvhT9q
-
-
Mashup Score: 3MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials - 1 year(s) ago
Key Points. Conversion from MRD− to MRD+ or from MRD+ to MRD− status during ixazomib or placebo maintenance modulates the risk of disease progression.Ixazomib p
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Sustained MRD-negativity = relevant endpoint for myeloma maintenance therapy. MRD dynamics in 1280 pts @BloodJournal @ASH_hematology @theMMRF @IMFmyeloma @HealthtreeMM #mmsm @BrunoPaiva_UNAV @LLSusa https://t.co/1qm4bodSIU
-
-
Mashup Score: 0
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of…
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MRD has become a very important biomarker in multiple myeloma. Tune in to our podcast w/ @mbeksac56, @BrunoPaiva_UNAV & @End_myeloma, who discuss exciting applications of MRD in myeloma: 🎧 https://t.co/WGkOHOcmpa #MMsm #mmMRD #HemOnc https://t.co/r2MCWdtJVF
-
-
Mashup Score: 0What’s Next for MRD in Myeloma? - 1 year(s) ago
Current techniques to monitor measurable residual disease (MRD) in patients with multiple myeloma (MM) often test bone marrow aspirates, b ut the noninvasive nature of testing peripheral blood is drawing the interest of researchers. MRD is one of the best available prognostic markers for patients with MM, according to Bruno Paiva, PharmD, PhD, Co-Director of the Flow Cytometry Platform and the Monoclonal Gammopathies Research Laboratory at the Clínica and CIMA Universidad de Navarra in Spain. In 2016,
Source: bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
What’s next for MRD in myeloma? In this feature, hear from @BrunoPaiva_UNAV of @CIMA_unav, @DrSNamburi of @ProvSwedCancRes, @ajjakubowiak of @UChicago, @DrSarahHolstein of @unmc, and Laura Notarfranchi, MD, of @unipr. 📚: https://t.co/0xQzlCRnZF https://t.co/BSglnKxg91
-
-
Mashup Score: 5MGUS-like calculator - 1 year(s) ago
Calculate MGUS-like profile & estimate clinical outcomes based on flow cytometry data on the frequency of bone marrow (BM) plasma cells (PC) and the percentages of normal and clonal PC within the BM PC compartment, at diagnosis. Clinical outcomes derived from more than 1500 patients enrolled in 5 PETHEMA/GEM clinical studies described in the manuscript: Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, et al. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined
Source: www.mgus-like.comCategories: Latest Headlines, Partners & KOLsTweet-
5⭐️Some pts with MM have MGUS type phenotype and have better prognosis. Although this calculator does not identify all of them, this is a useful resource for a newly diagnosed patient: @BrunoPaiva_UNAV Calculator: https://t.co/IQvlqY4KHW Source Article: https://t.co/NcEnorcmA3
-
-
Mashup Score: 0
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
ICYMI: What’s next for MRD in myeloma? In this new feature, @BrunoPaiva_UNAV of @CIMA_unav, @DrSNamburi of @ProvSwedCancRes, @ajjakubowiak of @UChicago, @DrSarahHolstein of @unmc, and Laura Notarfranchi, MD, of @unipr share their thoughts. 📚: https://t.co/0xQzlCQQa7 https://t.co/Hjzv3KMXza
-
-
Mashup Score: 0
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses methods for reliably assessing measurable residual disease (MRD) in patients with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our interview with @BrunoPaiva_UNAV from #COMy23, who discussed technical tips for accurate MRD assessment in multiple myeloma: 👉 https://t.co/79BcL5KQo3 👈 @COMyCongress #MMsm #mmMRD
-
-
Mashup Score: 1
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Source: Blood Cancers TodayCategories: Hematologists1, Latest HeadlinesTweet-
What’s next for MRD in myeloma? In this new feature, @BrunoPaiva_UNAV of @CIMA_unav, @DrSNamburi of @ProvSwedCancRes, @ajjakubowiak of @UChicago, @DrSarahHolstein of @unmc, and Laura Notarfranchi, MD, of @unipr share their thoughts. 📚: https://t.co/0xQzlCRnZF https://t.co/MY916l3sbB
-
-
Mashup Score: 2Definition and clinical significance of the MGUS-like phenotype in patients with monoclonal gammopathies - 1 year(s) ago
The Multiple Myeloma Hub was pleased to speak with steering committee member, Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is the definition and clinical significance of the MGUS–like phenotype in patients with monoclonal gammopathies?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Multiple Myeloma Hub was delighted to speak with @BrunoPaiva_UNAV on the topic of MGUS-like phenotype and other diagnostic challenges. Watch here 👉 https://t.co/AWB974Eo59 👈 #mmsm https://t.co/i2r7MelYgx
-
As March is #myelomaawarenessmonth, we wanted to share an update from the 20th International Myeloma Society (IMS) Annual Meeting | The value of #circulating #tumor cells for the staging of patients with #NDMM @BrunoPaiva_UNAV 📣🩸 👉 https://t.co/mEncmVUD57 #VJHemOnc #MMsm https://t.co/MVj6NdCFN1